Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanqiu Zhao

Showing results (121-130 of 195) with videos related to

Pageof 20
Sort By:
Plant Science : an International Journal of Experimental Plant Biology|April 25, 2024
PagPXYs improve drought tolerance by regulating reactive oxygen species homeostasis in the cambium of Populus alba × P. glandulosaCheng Jiang, Jiawei Wang, Xinyue Fu, et al.
Cell Death & Disease|July 15, 2018
Inhibition of the miR-192/215-Rab11-FIP2 axis suppresses human gastric cancer progressionXiaojing Zhang, Yin Peng, Yong Huang, et al.
Scientific Reports|February 13, 2024
A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancerYing Cheng, Chunjiao Wu, Lin Wu, et al.
Annals of Hematology|January 1, 2018
Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemiaHongli Zhao, Yanqiu Zhao, Yingmei Zhang, et al.
BMC Medicine|January 8, 2023
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa studyYuankai Shi, Jianying Zhou, Yanqiu Zhao, et al.
Marine Drugs|April 21, 2022
Pan-Genomic and Transcriptomic Analyses of Marine <i>Pseudoalteromonas agarivorans</i> Hao 2018 Revealed Its Genomic and Metabolic FeaturesYuhao Jv, Chenxiang Xi, Yanqiu Zhao, et al.
Eclinicalmedicine|January 30, 2023
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)Yuanyuan Zhao, Yunpeng Yang, Fangfang Gao, et al.
Blood|December 24, 2009
Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemiaJin Zhou, Yingmei Zhang, Jinmei Li, et al.
Journal for Immunotherapy of Cancer|August 19, 2023
Tislelizumab plus chemotherapy for patients with <i>EGFR</i>-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapyHua Zhong, Xueyan Zhang, Panwen Tian, et al.
Lung Cancer (Amsterdam, Netherlands)|October 22, 2025
Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trialXinyu Wu, Rui Wan, Lin Wu, et al.
Pageof 20

Showing results (121-130 of 195) with videos related to

Sort By:
Pageof 20
Plant Science : an International Journal of Experimental Plant Biology|April 25, 2024
PagPXYs improve drought tolerance by regulating reactive oxygen species homeostasis in the cambium of Populus alba × P. glandulosaCheng Jiang, Jiawei Wang, Xinyue Fu, et al.
Cell Death & Disease|July 15, 2018
Inhibition of the miR-192/215-Rab11-FIP2 axis suppresses human gastric cancer progressionXiaojing Zhang, Yin Peng, Yong Huang, et al.
Scientific Reports|February 13, 2024
A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancerYing Cheng, Chunjiao Wu, Lin Wu, et al.
Annals of Hematology|January 1, 2018
Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemiaHongli Zhao, Yanqiu Zhao, Yingmei Zhang, et al.
BMC Medicine|January 8, 2023
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa studyYuankai Shi, Jianying Zhou, Yanqiu Zhao, et al.
Marine Drugs|April 21, 2022
Pan-Genomic and Transcriptomic Analyses of Marine <i>Pseudoalteromonas agarivorans</i> Hao 2018 Revealed Its Genomic and Metabolic FeaturesYuhao Jv, Chenxiang Xi, Yanqiu Zhao, et al.
Eclinicalmedicine|January 30, 2023
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)Yuanyuan Zhao, Yunpeng Yang, Fangfang Gao, et al.
Blood|December 24, 2009
Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemiaJin Zhou, Yingmei Zhang, Jinmei Li, et al.
Journal for Immunotherapy of Cancer|August 19, 2023
Tislelizumab plus chemotherapy for patients with <i>EGFR</i>-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapyHua Zhong, Xueyan Zhang, Panwen Tian, et al.
Lung Cancer (Amsterdam, Netherlands)|October 22, 2025
Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trialXinyu Wu, Rui Wan, Lin Wu, et al.
Pageof 20